×
0 0 0 0.021015761821366 0.0297723292469352 0.0280210157618214 0.0280210157618214 0.0297723292469352
Stockreport

Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

AURINIA PHARMACEUTICALS INC OR (AUPH)  More Company Research Source: Business Wire
Last aurinia pharmaceuticals inc or earnings: 8/9 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.auriniapharma.com
PDF VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). VOS, which is a proprietary nanomicellar formulation, enables high concentrations of voclosporin to be incorporated into a clear aqueous, preservative-free solution for local delivery to the ocular surface. This patented formulation has the potential to result in improved efficacy, dosing frequency, and tolerability versus the current treatments for DES. This Phase 2 study is evaluating the ocular tolerability of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) at four weeks in subjects with mild to moderate DES. This robust head-to-head trial is recruiti [Read more]

IMPACT SNAPSHOT EVENT TIME: AUPH
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AUPH alerts

from News Quantified
Opt-in for
AUPH alerts

from News Quantified